ASH 2020
Fred Hutchinson Cancer Research Center’s latest findings on transplantation, cell therapies, precision medicine and more will be featured at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH).
This year's annual meeting will be held as a virtual event — featuring thousands of scientific abstracts highlighting updates on the most critical topics in hematology.
The ASH meeting provides an invaluable educational experience and the latest on the hottest topics in hematology. Attendess include top minds in the field and a global community of more than 25,000 hematology professionals from every subspecialty.
ASH President Events
Dr. Stephanie Lee
Professor and Associate Director, Clinical Research Division, Fred Hutch
Holder of the Giuliani/Oliver Press Endowed Chair in Cancer Research, Fred Hutch
President of American Society of Hematology
Fireside Chat
To kick off the ASH meeting, Dr. Lee will talk with Dr. Anthony Fauci, National Institute of Allergy and Infectious Diseases, National Institutes of Health, from 7a.m.-7:30 a.m. on Saturday, Dec. 5.
E. Donnall Thomas Lecture
Dr. Lee will chair the annual E. Donnall Thomas Lecture, named for the Hutch’s Nobel laureate Dr. Thomas, who would have turned 100 this year. This lectureship recognizes pioneering research achievements and is on Monday, Dec. 7, 1:30 p.m.-2:30 p.m.
Presidential Symposium
Dr. Lee will chair the discussion "Universal Donor Solutions in Hematology" on Tuesday, Dec. 8, 9:30 a.m. -11 a.m.
Featured Events
Dr. Sinéad Kinsella
Dr. Kinsella, a researcher in the lab of Dr. Jarrod Dudakov, will present findings on a new way of thymus regeneration in which a cell death process called pyroptosis is critical in releasing large numbers of signaling molecules that can trigger the thymus to repair itself.
Monday, Dec. 7, 2:45 p.m.
Dr. Mayzar Shadman
Dr. Shadman will share early results from the ongoing trial taking place at the Seattle Cancer Care Alliance, the Hutch’s clinical-care partner.
Saturday, Dec. 5, 7 a.m.-3:30 p.m.
Dr. Elizabeth Krakow
Dr. Krakow will present a phase I trial in progress. It uses a T-cell receptor therapy developed by Dr. Marie Bleakley to treat adult and pediatric patients who have relapsed after receiving a stem cell (blood and marrow) transplant for leukemia or other related conditions.
Sunday, Dec. 6, 2:15 p.m.
Highlights of Fred Hutch Presentations at ASH
Cellular Therapies | Transplantation and Other Clinical Studies | Precision Medicine and AML | Health Economics | Gene Editing | Cell Biology
Scientific Workshop: Age, performance status, and comorbidities in relation to IEC-associated toxicities (including ICANS) followed by live Q&A panel discussion
Presenter: Jordan Gauthier, M.D.
Thursday, Dec. 3, 2:45 p.m.-3:17 p.m.
Poster Presentation: High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics
Presenter: Jordan Gauthier, M.D., M.SC.
Abstract No. 1442
Saturday, Dec. 5, 7 a.m.-3:30 p.m.
ASH Virtual Poster Walk: Thursday, Dec. 10, 7 a.m.
Poster Presentation: Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Abstract No. 1443
Presenter: Mazyar Shadman, M.D.
Saturday, Dec. 5, 7 a.m. to 3:30 p.m.
Scientific Program, Live Q&A: Challenges in Cell Therapy: Relapse and Toxicities
Presenter: Aude Chapuis, M.D.
Saturday, Dec. 5, 9:30 a.m.-10:15 a.m.
Oral Poster: Phase I Study of Adoptive Immunotherapy with HA-1-Specific CD8+ and CD4+ Memory T Cells for Children and Adults with Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (HCT): Trial in Progress
Abstract No 492
Presenter Elizabeth F. Krakow, M.D., M.Sc.
Sunday, Dec. 6, 2:15 p.m.
Poster Presentation: Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy
Abstract No. 1959
Presenter: Quy Le, Ph.D.
Sunday, Dec. 6, 7 a.m.-3:30 p.m.
Poster Presentation: A Shared SF3B1 Neoantigen Is Presented on Primary Malignant Cells and Induced Pluripotent Stem Cell-Derived Hematopoietic Lines
Abstract No. 3265
Presenter: Melinda ann Biernacki, M.D.
Monday, Dec. 7, 7 a.m. - 3:30 p.m.
Poster Presentation: CD19 CAR T-cell
Abstract No. 3485
Presenter: Erin Mullane, D.N.P.
Monday, Dec. 7, 7 a.m.-3:30 p.m.
Poster Presentation: Novel CAR T Modules (Tmod) to Target HLA-Class I Loss in Lymphoma
Abstract No. 3370
Presenter: David Maloney, M.D., Ph.D.
Monday, Dec. 7, 7a.m.-3:30p.m.
Oral Presentation: Cytomegalovirus Promotes Aberrant Memory CD4 T Cell Differentiation and Immune Function after Allogeneic Stem Cell Transplantation
Abstract No. 423
Presenter: Albert Yeh, M.D.
Sunday, Dec. 6, 1:15 p.m.
Poster Presentation: Pembrolizumab with R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma: Long Term Follow up and Analysis of the Mechanism of Pdl-1 Tumor Expression
Abstract No. 2111
Presenter: Stephen D. Smith, M.D.
Sunday, Dec. 6, 7a.m.-3:30p.m.
Poster Presentation: Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib
Abstract No. 2947
Presenter: Mayzar Shadman, M.D., M.P.H.
Monday, Dec. 7, 7a.m.-3:30p.m.
Poster Presentation: Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Abstract No. 2935
Presenter: Ryan C. Lynch, M.D.
Monday, Dec. 7, 7a.m.-3:30p.m.
Poster Presentation: Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study
Abstract No. 2964
Presenter: Ryan C. Lynch, M.D.
Monday, Dec. 7, 7a.m.-3:30p.m.
Oral Presentation: Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts
Abstract No. 274
Presenter Rhonda E. Ries, M.A.
Saturday, Dec. 5, 2:30
Poster Presentation: Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access
Abstract No. 1973
Presenter: Katherine Tarlock, M.D.
Sunday, Dec. 6, 7 a.m.-3:30 p.m.
Poster Presentation: Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia
Abstract No. 1993
Presenter: Katherine Tarlock, M.D.
Sunday, Dec. 6, 7 a.m.-3:30 p.m.
Poster Presentation: Target-Informed Repurposing of Immunotherapies in AML — a Transcriptome Based Approach for Identifying Immediately Available Therapeutics
Abstract No. 2003
Presenter: Amanda R. Leonti, M.S.
Sunday, Dec. 6, 7 a.m.-3:30 p.m.
Poster Presentation: Comparison of Outcomes and Utilization of Therapy in Multiple Myeloma Patients in the USA and Alberta, Canada
Abstract No. 2516
Presenter: Andrew J. Cowan, M.D. (co-author Veena Shankaran, M.D.)
Sunday, Dec. 6, 7 a.m.-3 p.m.
Poster Presentation: Multiplex CRISPR/Cas9 Genome Editing Targeting the BCL11A/HBG Axis Maximizes Fetal Hemoglobin Reinduction but Generates Chromosomal Translocations Which Persist In Vivo
Abstract No. 2447
Presenter: Clare Samuelson
Sunday, Dec. 6, 7 a.m.-3 p.m.
Poster Presentation: Distinct Transcriptional signatures distinguish the emergence of multipotent progenitors and hematopoietic stem cells from endothelial precursors in the murine embryo
Abstract No. 908
Presenter: Tessa Dignum, B.S.
Saturday, Dec. 5, 7 a.m.-3:30 p.m.
Oral Presentation: Damage-Induced Pyroptotic Cell Death Facilitates Regeneration of the Thymus
Abstract No. 735
Presenters: Sinéad Kinsella, M.Sc., Ph.D and Jarrod A. Dudakov, Ph.D.
Monday, Dec. 7, 2:45 p.m.
Other Fred Hutch Experts with Research at ASH
Elihu Estey
Geoff Hill
Hans-Peter Kiem
Gary Lyman
Soheil Meshinchi
Effie Petersdorf
Jerry Radich
Mohammed Sorror
Monica Thakar
Latest ASH News
Media Coverage
Comparison of Therapy Outcomes in Multiple Myeloma Patients in US & Canada
Oncology Times | By Sarah LaCorte
ASH in :30 Seconds
Includes the Fireside Chat with ASH president Stephanie Lee of the Fred Hutchinson Cancer Research Center in Seattle
STAT
ASH 2020: Preclinical Models Identify CD74 as Potential Target for the Treatment of AML
Onco'Zine | By Peter Hoffland, Ph.D. | Dec. 8, 2020
VIDEO: 'Exciting' new CAR T developments presented at ASH
Healio | Dec. 9, 2020
Contact Our Media Relations Team
For more information or to arrange an interview, please email or call our media relations team.